Recent research have focused on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopaminergic communication. While GLP agonists are increasingly employed for treating type 2 diabetes, their unexpected effects on motivation circuits, specifically influenced by dopamine pathways, are gaining significant a